Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia

Sandra G. Resnick, Robert A. Rosenheck, Jose M. Canive, Cyril De Souza, T. Scott Stroup, Joseph Patrick McEvoy, Sonia Davis, Richard S.E. Keefe, Marvin Swartz, Jeffrey Lieberman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.

Original languageEnglish (US)
Pages (from-to)215-225
Number of pages11
JournalJournal of Behavioral Health Services and Research
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Perphenazine
schizophrenia
Antipsychotic Agents
Schizophrenia
medication
rehabilitation
olanzapine
Therapeutics
participation
Risperidone
first generation
Randomized Controlled Trials
Interviews
Research
interview
Psychiatric Rehabilitation

Keywords

  • Antipsychotics
  • Employment
  • Schizophrenia

ASJC Scopus subject areas

  • Health(social science)
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. / Resnick, Sandra G.; Rosenheck, Robert A.; Canive, Jose M.; De Souza, Cyril; Stroup, T. Scott; McEvoy, Joseph Patrick; Davis, Sonia; Keefe, Richard S.E.; Swartz, Marvin; Lieberman, Jeffrey.

In: Journal of Behavioral Health Services and Research, Vol. 35, No. 2, 01.04.2008, p. 215-225.

Research output: Contribution to journalArticle

Resnick, Sandra G. ; Rosenheck, Robert A. ; Canive, Jose M. ; De Souza, Cyril ; Stroup, T. Scott ; McEvoy, Joseph Patrick ; Davis, Sonia ; Keefe, Richard S.E. ; Swartz, Marvin ; Lieberman, Jeffrey. / Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. In: Journal of Behavioral Health Services and Research. 2008 ; Vol. 35, No. 2. pp. 215-225.
@article{d6779000dab34e398f0105bb96f30f5d,
title = "Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia",
abstract = "Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.",
keywords = "Antipsychotics, Employment, Schizophrenia",
author = "Resnick, {Sandra G.} and Rosenheck, {Robert A.} and Canive, {Jose M.} and {De Souza}, Cyril and Stroup, {T. Scott} and McEvoy, {Joseph Patrick} and Sonia Davis and Keefe, {Richard S.E.} and Marvin Swartz and Jeffrey Lieberman",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s11414-007-9101-3",
language = "English (US)",
volume = "35",
pages = "215--225",
journal = "Journal of Behavioral Health Services and Research",
issn = "1094-3412",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia

AU - Resnick, Sandra G.

AU - Rosenheck, Robert A.

AU - Canive, Jose M.

AU - De Souza, Cyril

AU - Stroup, T. Scott

AU - McEvoy, Joseph Patrick

AU - Davis, Sonia

AU - Keefe, Richard S.E.

AU - Swartz, Marvin

AU - Lieberman, Jeffrey

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.

AB - Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.

KW - Antipsychotics

KW - Employment

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=42449098056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449098056&partnerID=8YFLogxK

U2 - 10.1007/s11414-007-9101-3

DO - 10.1007/s11414-007-9101-3

M3 - Article

VL - 35

SP - 215

EP - 225

JO - Journal of Behavioral Health Services and Research

JF - Journal of Behavioral Health Services and Research

SN - 1094-3412

IS - 2

ER -